1. Perhimpunan Peneliti Hati Indonesia, Perhimpunan Dokter Spesialis Patologi Indonesia, Perhimpunan Dokter Spesialis Onkologi Radiasi Indonesia, Perkumpulan Subspesialis Radiologi Abdomen Indonesia, Perhimpunan Dokter Spesialis Bedah Digestif Indonesia. Epidemiologi dan Faktor Risiko Karsinoma Sel Hati. Konsensus Nasional Penatalaksanaan Karsinoma Sel Hati. (Perhimpunan Peneliti Hati Indonesia, Perhimpunan Dokter Spesialis Patologi Indonesia, Perhimpunan Dokter Spesialis Onkologi Radiasi Indonesia, Perkumpulan Subspesialis Radiologi Abdomen Indonesia, Perhimpunan Dokter Spesialis Bedah Digestif Indonesia, editor). Jakarta: Perhimpunan Peneliti Hati Indonesia. 2017.
2. Wu C, Lin J, Ho H, Su C, Lee T, Wang S, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology. 2014;147(1):143-51.
3. Terrault N, Bzowej N, Chang K, Hwang J, Jonas M, American Association for the Study of Liver Diseases. AASLD Guidelines for treatment of chronic hepatitis B. Hepatology. 2018;67(4):1560-99.
4. Garcia Rodriguez L, Soriano-Gabarro M, Bromley S, Lanas A, Soriano L. New use of low-dose aspirin and risk of colorectal cancer by stage at diagnosis: a nested case–control study in UK general practice. BMC Cancer. 2017;2017(17):637.
5. Coyle C, Cafferty F, Langley R. Aspirin and Colorectal Cancer Prevention and Treatment: Is It for Everyone? Current Colorectal Cancer Reports. 2016;2016(12):27-34.
6. Tsan Y, Lin M, Ho W, Chen P. Nucleoside analogues, Statins and the Risk of Hepatocellular Carcinoma In Patients With Hepatitis b Virus Infection. Value in Health. 2015;18(3):A193.
7. Yin J, Li N, Han Y, Xue J, Deng Y, Shi J, et al. Effect of Antiviral Treatment With Nucleotide/Nucleoside Analogs on Postoperative Prognosis of Hepatitis B Virus–Related Hepatocellular Carcinoma: A Two-Stage Longitudinal Clinical Study. Journal of Clinical Oncology. 2013;31(29):3647-55.
8. Baran B. Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma. World Journal of Hepatology. 2015;7(13):1742-54.
9. Perhimpunan Peneliti Hati Indonesia. Indikasi Terapi. In: Indonesia, PPH, editor. Konsensus Nasional Penatalaksanaan Hepatitis B. Jakarta: Perhimpunan Peneliti Hati Indonesia. 2017. p. 6.
10. Chen H, Cai W, Chu E, Tang J, Wong C-C, Wong S, et al. Hepatic cyclooxygenase-2 overexpression induced spontaneous hepatocellular carcinoma formation in mice. Oncogene. 2017;36(31):4415-26.
11. Lee T, Hsu Y, Tseng H, Yu S, Lin J, Wu M, et al. Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. JAMA Internal Medicine. 2019;2019(1):E1-8.
12. Simon T, Ma Y, Ludvigsson J, Chong D, Giovannucci E, Fuchs C, et al. Association Between Aspirin Use and Risk of Hepatocellular Carcinoma. JAMA Oncology. 2018;4(12):1683-90.
13. Young S, Chau G, Lee I-C, Yeh Y-C, Huo T-L, Su C, et al. Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection. Journal of the Formosan Medical Association. 2020;119(1):218-29.
14. Petrick J, Sahasrabuddhe V, Chan A, Alavanja M, Beane-Freeman L, Buring J, et al. NSAID use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The Liver Cancer Pooling Project. Cancer Prevention Research (Phila). 2015;8(12):1156-62.
15. Hwang I, Chang J, Kim K, Park S. Aspirin Use and Risk of Hepatocellular Carcinoma in a National Cohort Study of Korean Adults. Scientific Reports. 2018;8(1):4968.
16. Simon T, Chan A. Reduced Hepatocellular Carcinoma Risk vs Bleeding Risk Associated With Aspirin—In Reply. JAMA. 2019;5(6):911-2.